Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Cathepsin D / CTSD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTSD Recombinant Protein (Zymogen/Active) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CTSD Products |
| Gene Delivery | CTSD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CTSD Products |
| Benchmark Ab | Anti-CTSD (Sequence of Clinical Clones) Recombinant positive control. |
View CTSD Products |
| Validator | CTSD siRNA Set For knockdown verification. |
View CTSD Products |
| Related Target A | CTSE (Cathepsin E) Closely related aspartic protease; essential for selectivity counter-screening. |
View CTSE Products |
| Related Target B | CTSB (Cathepsin B) Lysosomal cysteine protease; co-expressed in tumor microenvironments. |
View CTSB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species selectivity (Human vs. Cyno/Mouse) | Human, mouse, and cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter-screening (CTSD vs. CTSE) | Homolog panels (CTSE, CTSB, CTSL) strictly verified by mass spectrometry and sequence analysis |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included as assay standards |
| False Positives | Validated siRNA sets included for target-specific knockdown validation |
Live Cathepsin D / CTSD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Cathepsin D / CTSD therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and ADC-related lysosomal target-cleavable strategies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective, pH-dependent conformation transitions to avoid systemic toxicities associated with off-target aspartic protease inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Alzheimer's Disease, Solid Tumors | Selectivity Assay (Need Mutant vs WT Proteins and CTSE counter-screening panel) |
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Breast Cancer, TNBC | pH-dependent binding assays (Need HEK293-expressed native glycosylated CTSD) |
| ADC & Linker Validation | Global ADC Developers | Metastatic Solid Tumors | Lysosomal Cleavage Assay (Need highly pure, active CTSD enzymes) |